UCLA Health Jonsson Comprehensive Cancer Center: ESMO - Analysis Reinforces Survival Benefits of Targeted Therapy for Advanced Pancreatic Cancer
October 24, 2026
October 24, 2026
LOS ANGELES, California, Oct. 24 (TNSxrep) -- The UCLA Health Jonsson Comprehensive Cancer Center issued the following news release:
* * *
ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer
Additional findings from phase 3 trial suggest daraxonrasib improves survival across different RAS mutations, chemotherapy treatment groups and prior treatment settings
October 23, 2026
A new analy . . .
* * *
ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer
Additional findings from phase 3 trial suggest daraxonrasib improves survival across different RAS mutations, chemotherapy treatment groups and prior treatment settings
October 23, 2026
A new analy . . .